NASDAQ:XNCRXencor Stock Price, Forecast & News

$31.95

-1.00 (-3.03 %)

(As of 07/9/2020 04:00 PM ET)

Add

Compare

Today's Range

$31.89

Now: $31.95▼

$33.36

50-Day Range

$28.43

MA: $31.08▼

$32.95

52-Week Range

$19.35

Now: $31.95▼

$46.33

Volume175,775 shs

Average Volume473,776 shs

Market Capitalization$1.82 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.07

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Beat the Market (BTM) Rank^™

3.2 Analyst's Opinion

Consensus Rating
Xencor has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 7 buy ratings, 1 hold rating, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.50, Xencor has a potential upside of 26.8% from its current price of $31.95.
Amount of Analyst Coverage
Xencor has only been the subject of 4 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Xencor has received 439 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Xencor has received 284 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Xencor has received 60.72% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote “Outperform” if you believe XNCR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Xencor does not currently pay a dividend.
Dividend Growth
Xencor does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xencor insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.66% of the stock of Xencor is held by insiders.
Percentage Held by Institutions
90.03% of the stock of Xencor is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Xencor are expected to grow in the coming year, from ($1.75) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xencor is -29.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xencor is -29.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xencor has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:XNCR

Previous Symbol

CUSIPN/A

CIK1326732

Webwww.xencor.com

Phone626-305-5900

Debt

Debt-to-Equity Ratio0.01

Current Ratio8.92

Quick Ratio8.92

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$156.70 million

Price / Sales11.62

Cash Flow$0.50 per share

Price / Cash Flow63.28

Book Value$10.46 per share

Price / Book3.05

Profitability

EPS (Most Recent Fiscal Year)$0.46

Net Income$26.88 million

Net Margins-79.39%

Return on Equity-10.40%

Return on Assets-9.24%

Miscellaneous

Employees156

Outstanding Shares57,005,000

Market Cap$1.82 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

Xencor (NASDAQ:XNCR) Frequently Asked Questions

How has Xencor's stock been impacted by COVID-19 (Coronavirus)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XNCR stock has increased by 13.6% and is now trading at $31.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xencor?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 3 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Xencor.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xencor.

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.28. The biopharmaceutical company earned $32.39 million during the quarter, compared to analysts' expectations of $12.33 million. Xencor had a negative return on equity of 10.40% and a negative net margin of 79.39%. View Xencor's earnings history.

What price target have analysts set for XNCR?

11 brokerages have issued 12 month price targets for Xencor's stock. Their forecasts range from $21.00 to $54.00. On average, they anticipate Xencor's share price to reach $40.50 in the next year. This suggests a possible upside of 26.8% from the stock's current price. View analysts' price targets for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (5/10/2020)
2. Nomura Securities analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)

Has Xencor been receiving favorable news coverage?

Media stories about XNCR stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xencor earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Xencor.

Who are some of Xencor's key competitors?

Some companies that are related to Xencor include Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Legend Biotech (LEGN), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK) and Nektar Therapeutics (NKTR). View all competitors.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Apollo Global Management (APO), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Fossil Group (FOSL), NVIDIA (NVDA) and Abercrombie & Fitch (ANF).

Who are Xencor's key executives?

Xencor's management team includes the following people:

Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.02%). Company insiders that own Xencor stock include Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III, Paul A Foster and Ronin Capital, Llc. View institutional ownership trends for Xencor.

Which institutional investors are buying Xencor stock?

XNCR stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for Xencor.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $31.95.

How big of a company is Xencor?

Xencor has a market capitalization of $1.82 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings